ADiTx Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


About ADiTx Therapeutics

ADiTx Therapeutics is a biotechnology company developing a nucleic acid-based technology to selectively suppress immune cells involved in the rejection of transplanted tissues and organs. The company has an exclusive worldwide license for commercializing a nucleic acid-based technology named Apoptotic DNA Immunotherapy (ADi) which utilizes an approach that mimics the way our bodies naturally induce tolerance to our own tissues. While immune suppression requires continuous administration to prevent rejection of a transplanted organ, induction of tolerance has the potential to retrain the immune system to accept the organ for longer periods of time. Thus, ADi may allow patients to live with transplanted organs with significantly reduced dependence on immune suppression.

ADiTx Therapeutics Headquarter Location

11161 Anderson St Suite 105-10014

Loma Linda, California, 92354,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ADiTx Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ADiTx Therapeutics is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

ADiTx Therapeutics Patents

ADiTx Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Antibodies
  • Biochemistry methods
  • Immune system
patents chart

Application Date

Grant Date


Related Topics



Immune system, Immunology, Antibodies, Biochemistry methods, Proteins


Application Date


Grant Date


Related Topics

Immune system, Immunology, Antibodies, Biochemistry methods, Proteins



Latest ADiTx Therapeutics News

Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors

Jun 18, 2021

Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors 0 MOUNTAIN VIEW, Calif.–( BUSINESS WIRE )– Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. “As a new independent director of Aditxt’s board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals,” said Amro Albanna, co-founder and CEO of Aditxt. “We look forward to working with Dr. Chung as we establish our portfolio of first-in-human clinical studies, launch new high-growth verticals for our AditxtScoreTM immune…

ADiTx Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ADiTx Therapeutics Rank

  • When was ADiTx Therapeutics founded?

    ADiTx Therapeutics was founded in 2017.

  • Where is ADiTx Therapeutics's headquarters?

    ADiTx Therapeutics's headquarters is located at 11161 Anderson St, Loma Linda.

  • What is ADiTx Therapeutics's latest funding round?

    ADiTx Therapeutics's latest funding round is IPO.

  • How much did ADiTx Therapeutics raise?

    ADiTx Therapeutics raised a total of $370K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.